Screener
BridgeBio Pharma BBIO Deferred Royalty Obligation Net
Deferred Royalty Obligation Net at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept bbio:DeferredRoyaltyObligationNet.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| 2029 Notes, net | 741,918 | 740,890 |
| 2031 Notes, net | 565,528 | 564,565 |
| 2033 Notes, net | 620,087 | — |
| Deferred royalty obligations, net (3) | 879,374 | 855,030 |
| Operating lease liabilities, net of current portion | 14,973 | 3,811 |
| Deferred revenue, net of current portion | 10,424 | 13,080 |
| Other long-term liabilities | 240 | 244 |
| Total liabilities | 3,723,192 | 3,012,606 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's deferred royalty obligation net?
- BridgeBio Pharma (BBIO) reported deferred royalty obligation net of $879.37M in Q2 2026.
- How has BridgeBio Pharma's deferred royalty obligation net changed year-over-year?
- BridgeBio Pharma's deferred royalty obligation net increased by 8.0% year-over-year, from $813.96M to $879.37M.
- What does deferred royalty obligation net mean?
- Deferred Royalty Obligation Net as reported by BridgeBio Pharma, Inc. Common Stock.
Ask your AI about BridgeBio Pharma's deferred royalty obligation net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude